Trial Profile
(C-SHOT1601)Phase II study of bortezomib plus Lenalidomide and dexamethasone (Once weekly BLd) for elderly or transplant-ineligible patients with untreated symptomatic multiple myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2020
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 23 Apr 2020 Planned End Date changed from 28 Feb 2019 to 30 Sep 2020.
- 23 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 13 May 2016 New trial record